FY2025 Earnings Estimate for Nkarta Issued By William Blair

Nkarta, Inc. (NASDAQ:NKTX - Free Report) - Investment analysts at William Blair lifted their FY2025 earnings per share estimates for Nkarta in a research note issued to investors on Tuesday, November 11th. William Blair analyst S. Corwin now anticipates that the company will earn ($1.36) per share for the year, up from their previous forecast of ($1.38). The consensus estimate for Nkarta's current full-year earnings is ($1.70) per share. William Blair also issued estimates for Nkarta's FY2026 earnings at ($1.29) EPS.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03.

Other equities research analysts have also issued research reports about the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Nkarta in a research note on Friday, October 31st. Needham & Company LLC restated a "buy" rating and issued a $10.00 target price on shares of Nkarta in a report on Wednesday, August 13th. Wall Street Zen raised shares of Nkarta from a "sell" rating to a "hold" rating in a research note on Saturday, October 25th. Finally, Stifel Nicolaus dropped their price target on shares of Nkarta from $12.00 to $11.00 and set a "buy" rating for the company in a research report on Tuesday. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $13.25.

Get Our Latest Stock Analysis on Nkarta

Nkarta Stock Down 2.5%

NASDAQ NKTX opened at $1.96 on Thursday. The company has a 50-day simple moving average of $2.13 and a two-hundred day simple moving average of $2.01. Nkarta has a 12-month low of $1.31 and a 12-month high of $3.18. The firm has a market cap of $139.22 million, a price-to-earnings ratio of -1.42 and a beta of 0.86.

Institutional Investors Weigh In On Nkarta

Institutional investors and hedge funds have recently modified their holdings of the stock. Savant Capital LLC purchased a new position in shares of Nkarta during the second quarter valued at about $36,000. SG Americas Securities LLC boosted its position in Nkarta by 35.0% during the 3rd quarter. SG Americas Securities LLC now owns 23,663 shares of the company's stock valued at $49,000 after acquiring an additional 6,141 shares in the last quarter. CWM LLC boosted its position in Nkarta by 3,437.3% during the 1st quarter. CWM LLC now owns 28,157 shares of the company's stock valued at $52,000 after acquiring an additional 27,361 shares in the last quarter. Bailard Inc. purchased a new position in shares of Nkarta during the 3rd quarter worth approximately $61,000. Finally, Cerity Partners LLC bought a new position in shares of Nkarta in the 1st quarter worth approximately $55,000. 80.54% of the stock is owned by hedge funds and other institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.

Featured Articles

• Five stocks we like better than Nkarta
• Differences Between Momentum Investing and Long Term Investing
• 3 Reasons On Holding’s Sell-Off Is Over and New Highs Are Coming
• What is MarketRank™? How to Use it
• As Warren Buffett Nears His Exit, Berkshire's Amassed Record Cash
• 3 Monster Growth Stocks to Buy Now
• Rare Earth Stocks: The Truce That Isn't a Truce

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nkarta Right Now?

Before you consider Nkarta, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.

While Nkarta currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here